Rodrigo Dienstmann

Research interests

Publications

• ESMO Guidance for Reporting Oncology real-World evidence (GROW)

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.10.001

• The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

  Nature Cancer · 2022 · https://doi.org/10.1038/s43018-022-00332-x

• High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  Nature Communications · 2022 · https://doi.org/10.1038/s41467-022-32828-6

• A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

  Radiology · 2021 · https://doi.org/10.1148/radiol.2021200928

• A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-020-0603-8

• Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.06.003

• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.014

• New clinical trial designs in the era of precision medicine

  Molecular Oncology · 2019 · https://doi.org/10.1002/1878-0261.12465

• Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-19-2226

• Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz287

• A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

  EMBO Molecular Medicine · 2018 · https://doi.org/10.15252/emmm.201809172

• A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

  Annals of Oncology · 2018 · 10.1093/annonc/mdy263

• Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  Genome Medicine · 2018 · https://doi.org/10.1186/s13073-018-0531-8

• Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

  Nature reviews. Cancer · 2017 · 10.1038/nrc.2016.126

• Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies

  Clinical Cancer Research · 2017 · https://doi.org/10.1158/1078-0432.ccr-17-1234

• Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx052

• Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx112

• Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.60.7341

• Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

  Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-14-3081

• The consensus molecular subtypes of colorectal cancer

  Nature Medicine · 2015 · https://doi.org/10.1038/nm.3967

• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  Molecular Cancer Therapeutics · 2014 · https://doi.org/10.1158/1535-7163.mct-13-0639

• Development of PI3K inhibitors: lessons learned from early clinical trials

  Nature Reviews Clinical Oncology · 2013 · https://doi.org/10.1038/nrclinonc.2013.10

• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt419

Current projects

No projects listed.